A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial: Adapalene-BPO maintenance therapy prevents relapse
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acne vulgaris is a chronic and frequently recurring disease. A fixed-dose adapalene-benzoyl peroxide (adapalene-BPO) gel is an efficacious and safe acne treatment. OBJECTIVES: To assess the long-term effect of adapalene-BPO on relapse prevention among patients with severe acne after successful initial treatments. METHODS: This is a multicentre, double-blind, randomized and controlled study. In total, 243 subjects who had severe acne vulgaris and at least 50% global improvement after a previous 12-week treatment were randomized into the present study to receive adapalene-BPO gel or its vehicle once daily for 24 weeks. RESULTS: At week 24, compared with vehicle, adapalene-BPO resulted in significantly higher lesion maintenance success rate (defined as having at least 50% improvement in lesion counts achieved in initial treatment) for all types of lesions (total lesions: 78·9% vs. 45·8%; inflammatory lesions: 78·0% vs. 48·3%; noninflammatory lesions: 78·0% vs. 43·3%; all P < 0·001). Significantly more subjects with adapalene-BPO than with vehicle had the same or better Investigator's Global Assessment score at week 24 than at baseline (70·7% vs. 34·2%; P < 0·001). The time when 25% of subjects relapsed was 175 days with adapalene-BPO and 56 days with vehicle (17 weeks earlier; P < 0·0001). Adapalene-BPO led to further decrease of lesion counts during the study and 45·7% of subjects were 'clear' or 'almost clear' at week 24. It was also safe and well tolerated in the study. CONCLUSIONS: Adapalene-BPO not only prevents the occurrence of relapse among patients with severe acne, but also continues to reduce disease symptoms during 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thiboutot, D. M., Weiss, J., Bucko, A., Eichenfield, L., Jones, T., Clark, S., Liu, Y., Graeber, M., & Kang, S. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.06.006 · Cited by 183
Self-citationGollnick, H. P. M., Draelos, Z., Glenn, M. J., Rosoph, L. A., Kaszuba, A., Cornelison, R., Gore, B., Liu, Y., Graeber, M., & for the Adapalene-BPO Study Group (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09209.x · Cited by 128
Cited by
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Thiboutot, D. M., Dréno, B., Abanmi, A., Alexis, A. F., Araviiskaia, E., Barona Cabal, M. I., Bettoli, V., Casintahan, F., Chow, S., da Costa, A., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.078 · Cited by 418
Management of Acne Vulgaris: A Review
Eichenfield, D. Z., Sprague, J., & Eichenfield, L. F. (2021) · JAMA · doi:10.1001/jama.2021.17633 · Cited by 389
Systematic review of antibiotic resistance in acne: an increasing topical and oral threat
Walsh, T. R., Efthimiou, J., & Dréno, B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00527-7 · Cited by 314
Kulthanan, K., Trakanwittayarak, S., Tuchinda, P., Chularojanamontri, L., Limphoka, P., & Varothai, S. (2020) · BioMed Research International · doi:10.1155/2020/2857812 · Cited by 24
“Among 5 previous studies of maintenance phase of acne therapy [8, 23, 25, 26, 31], Thielitz et al.”
BackgroundUse of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort
Evaristo, L. S. B. F., & Bagatin, E. (2019) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2018.054405072019 · Cited by 11
Metadata
- Authors
- Poulin, Y., Sanchez, N. P., Bucko, A., Fowler, J., Jarratt, M., Kempers, S., Kerrouche, N., Dhuin, J.-C., & Kunynetz, R.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-20
- Volume
- 164
- Issue
- 6
- Pages
- 1376-1382
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W1580715943
- Cited by
- 58
- References
- 2
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.